Post reply

Warning: this topic has not been posted in for at least 365 days.
Unless you're sure you want to reply, please consider starting a new topic.

Note: this post will not display until it's been approved by a moderator.

Message icon:

(Clear Attachment)
(more attachments)
Allowed file types: gif, jpg, pdf, png, kmz, rar, jpeg
Restrictions: 3 per post, maximum total size 1280KB, maximum individual size 640KB
Note that any files attached will not be displayed until approved by a moderator.
Type the letters shown in the picture
Listen to the letters / Request another image

Type the letters shown in the picture:
How do people in Korat call the Thao Suranaree Monument in the center of town? (Mundo/Yamo/Supa/Mall):
What makes three plus two?:

shortcuts: hit alt+s to submit/post or alt+p to preview

Topic Summary

Posted by: Roger
« on: February 11, 2018, 09:16:32 AM »

Linking in with the last post here some time ago, Juno a CAR-T Company in the USA was sold recently for $9 billion. Scancell's current valuation is about £30 million and the share price is now around 12 pence ! $9 billion would make the SP £20 or thereabouts LOL  :spin

I posted this elsewhere but for anyone interested, a paste here might give continuity :-

Just an update for anyone interested - Scancell's 2nd platform - Moditope 3
In a nutshell, 144 teams entered for CRUK's Grand Challenge - up to £20 million research grants.
Scancell are on the shortlist of 10. Their topic for the challenge will be Modi3 and Scancell's Prof Lindy Durrant, will lead a team of 15 eminent Oncologist/Scientists in preparing the paper in cooperation with Genentech, (a major Biotech owned by Roche), BioNTech in Germany who are using Modi to adapt CAR-T type therapy, and ISA Pharma of Germany. Pundits say that Moditope, taking away 100% of 'heavy tumour load' in pre-clinical work, can be an industry in itself. Share price 12 pence !

Official statements :-

''Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is proud to announce that an international, multi-disciplinary team of the leading cancer immunotherapy scientists in Europe and the US, led by Prof. Lindy Durrant, Chief Scientific Officer of Scancell, and in partnership with Genentech, BioNtech and ISA pharmaceuticals1, has been shortlisted to the final stages of Cancer Research UK's Grand Challenge2 - an ambitious series of £20 million global grants tackling some of the toughest questions in cancer research.  The team will collaborate on a project entitled "Project Blueprint: Eradicating established tumours with unique cancer vaccines".

Project Blueprint aims to eliminate tumours by treating patients with specific vaccines.  Prof. Lindy Durrant will lead an international world-class team to investigate the full potential of the tumour vaccine concept by building blueprints for an effective therapy for patients with most types of cancer.  The project focus will be on head and neck cancer, glioblastoma, lung, and pancreatic cancer - all of which currently have a poor prognosis - in which treatment with Modi-3, a product generated from Scancell's Moditope® platform will be assessed alongside vaccines targeting new mutations within individual patients' tumours

And :-

'Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, notes that European Patent Office has announced its intention to grant Scancell's application for a European patent for its Moditope® immunotherapy platform.

This case is key to the protection of the Company's pipeline of Moditope® vaccines for the treatment of cancer and will provide commercial exclusivity in all major European territories including: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey.  Counterparts to this patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

Cliff Holloway, Chief Executive Officer of Scancell, commented:
"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate.  This is a key case for the Company as we progress development of our Moditope® platform and provides further protection for Scancell's innovative cancer vaccine technologies."

*       *       *       *

Me again - Scancell now arguably have 4 platforms for cancer treatment.

Immunobody and Immunobody combo with checkpoint inhibitor
An Immunobody trial, SCIB1 for melanoma - 16 of 18 resected Patients with a prognosis of months, are alive after 5 years or more. In pre-clinical trials in combo - almost 100% of cancers were halted.

Moditope with TCR therapy (BioNTech)
In pre clinical studies, Moditope took away 100% of heavy tumour load and Moditope it seems, can be engineered to address most cancers.
(There's some real science here, a wide Patent is shortly to be granted).

You can read the Scancell news on under the header 'RNS'.

Posted by: Roger
« on: November 08, 2015, 07:08:21 AM »

A really interesting article about the development of CAR-T immunotherapy for treating cancer can be found on enter SCLP. A post by 'Crumbs' 15.13 yesterday links to 'Seeking Alpha'. Though quite technical it's very thorough and well worth a read and when you see the valuation on these Biotech Companies it gives perspective to the potential in what SCLP are doing. And SCLP valued at around £50 million atm.
I wish all these Companies the best luck BUT they do not have two plug and play platforms for cancer vaccines with low cost manufacture, no side effects, no toxicity and able to address a high percentage of patients.
Posted by: Roger
« on: November 07, 2015, 11:14:42 AM »

No announcement was forthcoming at the recent Scancell AGM. Stalwart investors believe that the BoD are hamstrung by the confidentiality of discussions going on but the Share Price fell badly, on very small volumes - one of the vagaries of the AIM market.
The science is unchanged with amazing results on Stage 3/4 Melanoma patients, some of whom are alive after nearly 4 years. We are awaiting an update on a higher dose cohort (8mg) of patients who had showed immediately a 10 times response over the 4 mg dose. 
So there it is - resolve needed for long term investors such as myself ! With the share price stuck at around 16 pence Scancell IMO is an amazing investment prospect.
As for me, eating humble pie ATM but 100% confident still.
There was good news worldwide last week when a last ditch attempt to save a baby girl from leukaemia using Immunotherapy, (Car-T) led to an apparent full recovery. One patient ! No conclusions really possible from a one-off pre-clinical punt but SCLP still struggle for publicity !
Strange world.
Posted by: Roger
« on: October 15, 2015, 02:52:49 PM »

When I returned to my other BB, Scancell, I see there is also a 5 minute interview on the 'proactive' website, with our CEO Richard Goodfellow and he talks openly about the possibility of a NASDAQ listing. Exciting times.
Sorry - my 'Do you know' sentence in the last post looks a bit patronising. But fantastic it is ! I'm a bit excited about this. ATB
Posted by: Roger
« on: October 15, 2015, 02:24:49 PM »

Scancell's progress continues - one new USA based Non-exec Director and one USA based advisor appointed this week.
Biotech values in the USA, though currently slumping, are massive compared to the UK and it looks as if the BoD are going to take this one over the water for further development.
The current share price of Scancell is just laughable - 22.75 pence. Just low because the AIM market functions badly and our Board keep a lowish profile.
That said there is an article today in - you can find it on the homepage under 'Ambitious Scancell ....'. It's a good read and will explain Scancell a lot better than I can.
Immunotherapy IS going to take over in the field of cancer treatment. You'll read many big stories in the Press but Scancell have a successful 'off the shelf' cancer vaccine with no toxicity and therefore no real side effects.
The 'Immunobody' platform is a plug and play system for vaccines and has been described as the 'universal antigen delivery system' allowing many different cancers to be addressed. SCIB1 the first vaccine soon going into Phase 3 trials is being described now as 'preventing the re-occurence of melanoma'. Do you know how fantastic that is ? Melanoma is brutal just brutal.
And the Moditope platform is ready  in 2016 for trials in latest stage cancers.
It's the Scancell AGM this week and many think that an announcement re. a Phase 3 collaboration with big Pharma and hopefully a 'liquidity event' will be forthcoming.
Keep well all.

Posted by: Roger
« on: August 01, 2015, 05:59:56 AM »

An excellent webcast from Scancell's CEO Richard Goodfellow was posted on the website yesterday. The main news is about a collaboration with ImmunID who have developed a procedure for analysing a person's immune system. Immunotherapy is a red hot area of development in cancer treatments with new drugs and vaccines emerging. ImmunID's science can help the selection of the most appropriate therapy.
The days of chemo and radiotherapy may be numbered.
Scancell's discussions with Big Pharma under CDA continue and the countdown is on for a large Phase 3 trial of the SCIB1 vaccine for melanoma. SCIB1 is particularly able to protect resected Patients from reoccurrence at all stages.
Scancell's Immunobody and Moditope platforms are IMO dramatically undervalued at a market capitalisation of GBP60 million compared to US Companies with much less science to offer. Scancell's vaccines should be available at a reasonable cost one day while the emerging checkpoint inhibitors and Car-T therapies are expensive beyond the means of most at an annual cost of GBP100,000 or more. AND these new drugs, (which have had a lot of press coverage in recent months), have some terrible side effects.
Scancells vaccine might cause a sore arm at worst!
Have a rake through the website or read for chat. GLA
Posted by: Roger
« on: June 05, 2015, 01:45:48 PM »

To view a story about one Patient on this trial
'Cancer vaccines by Inanaco.'
(about 10 tubes down).
Posted by: Roger
« on: June 05, 2015, 05:21:04 AM »

Yesterday p.m. there were some very interesting and informed discussions on LSE.CO.UK/SCLP dealing with much vaunted 'Checkpoint Inhibitors' and 'CAR-T' therapies, the other runners in the now red hot race for Immunotherapy treatments for cancer, replacing chemo and radiology.
Amongst other thoughts on that BB, early use of Scancell's SCIB1 in melanoma treatment, will mean a market potential 31 times the size of the CAR-T market.
Scancell shareholders are waiting for their first deal, which cannot now be far away !
One hopes.

Posted by: Roger
« on: June 04, 2015, 05:01:54 PM »

Scancell gave a presentation at the leading world Cancer conference, ASCO in Chicago - just finished. (Clinical Oncology).
The UK papers and media picked up strongly on a presentation by BMS about their new 'checkpoint inhibitors' and there was a big and inaccurate hullabaloo about a coming 'cure' for cancers.
Almost unnoticed at ASCO, by comparison, Scancell's update on melanoma trial progress reports :-
............. all 16 patients with resected disease are still alive
............. recorded survival (so far) of Stage 3 patients is 34 months and Stage 4 patients is 31 months.
............. only 31% of patients had any recurrence but 69% have been disease free for between 27-46 mths.
............. the vaccine was safe and well tolerated
Scancell's results far exceed what BMS are claiming for their Yervoy combo treatment which has a prohibitive cost of GBP 100,000 pa at the very least.
Side effects of the BMS trial include 5 deaths and meningitis/ hepatitis etc.
Scancells SCIB1 vaccine is non-toxic, works better than the alternatives and is the only treatment available for fully resected patients to keep the disease at bay. Combining SCIB1 with checkpoint inhibitors enhances their results. Scancell's vaccine is almost certain to be much more affordable.
AND THEN, Scancells second platform, Moditope, will attack advanced tumours effectively.
Exciting times.
A 'youtube' under Scancell about 'Tom' is worth watching.
Much more to come - still holding my shares !
More on
Posted by: Roger
« on: December 10, 2014, 04:12:25 PM »

Just an update.
Too much biking around Cha am today for me, but if anyone is interested - have a look at - the  'RNS' today. Or - 'Torquay fan' 12.33 post in Share Chat says it for me !
Up to you and DYOR but this 34.75 pence per share might be a fair bit more, one day soon.
Immunotherapy generally looks like kicking other treatments for cancer into touch before too long - the ambition being - to turn cancer into a 'chronic' disease.
Posted by: Roger
« on: October 14, 2014, 02:46:56 PM »

Scancell are holding their AGM today and there will be an update on the progress of both Immunobody and Moditope platforms after the meeting. An RNS has been issued and there is a lot of detail about the trials.
Most interestingly, both platforms are being evaluated by 'a number of ' Big Pharmas under CDA agreements ...........
The review of the SCIB1 vaccine for advanced melanoma patients, notes that all 16 patients with fully resected disease are still alive with a median survival time of 26 months so far. (The USA market alone would be 45% of 360,000 patients).
SCIB2 on stream for lung, oesaphageal, gastric, ovarian, bladder cancers.
Influenza, Epstein Barr virus and other infectious diseases also are targeted.
Stunning stuff but I am not 'technical' so refer you to or to read more.

Posted by: Roger
« on: August 12, 2014, 03:09:43 PM »

Interesting news today - a combination trial of Scancell vaccine and CheckPoint inhibitors induced 'potent T-cell responses with increased T-cell infiltration resulting in tumour rejection and long term survival in 85% of animals'. The battle against cancer may truly be on the launch-pad.
Startling ! Details on under RNS announcements.

Posted by: Roger
« on: June 06, 2014, 04:43:41 PM »

Two Scancell RNS Announcements in one week !
Today it was announced that a Patent has been granted for Scancell's DNA Immunobody vaccine in the USA - the Patents for the Protein Immunobody vaccines are already in place Worldwide.
Patent Applications for the next generation of Scancell's achievements, the Moditope platorm, are progressing well.
Following the ASCO event in the USA, you may have seen wide coverage of new 'wonder' drugs for treating cancers - checkpoint inhibitors known as PD-1 and PD-L1. Publicity paid for by the World's largest Pharmas.
Checkpoint inhibitors help only 30-40% of sufferers and can have disastrous side effects - the hope is that ALL these CI's will benefit from being used at lower doses to avoid the side effects but in combination with Scancell vaccine - (even though it may be that Scancell vaccines on their own will outperform a combo).
In 3 years or so, news of Moditope trials will come along and by all reports, be even more powerful - in oncology and other conditions too.
SCLP shares are below the radar and at a laughable 33p and the SP will go silly but silly when the first licensing deal arrives. DYOR.
More importantly - great hopes for sufferers in the future.

Posted by: Roger
« on: June 02, 2014, 05:42:47 PM »

Some more Scancell news today from the Annual Meeting of ASCO (American Society of Clinical Oncology).

Prof. Poulam Patel, (the Chief Investigator for the trial of SCIB1), "although checkpoint inhibitors, (PD1 and PDli), deliver clinical results, the long term benefits are only apparent in 1/3 of patients. Taking the break off T-cells with checkpoint inhibitors and pressing the accelerator with active Immunotherapies such as SCIB1 may be an effective way of overwhelming the disease.......... ".
(The rules about what can be said during such trials are extremely tight - the use of the word 'overwhelming' is exciting indeed).

Scancell have been trialling 8mg doses, (up from 4mg), and "Immune responses to the 8mg dose were up to 10 times higher than those seen in the 4mg group. High frequencies of melanoma specific T-cells exceeding 2% of total blood lymphocytes were observed".
(Apparently this is really significant).

Noted that only 2 of 25 stage 3/4 melanoma patients receiving 2-8mg doses of SCIB1 have died since the trial began in 2010.

Anyone interested can read the whole release of news on - look at RNS announcements.

Posted by: Roger
« on: April 07, 2014, 06:45:49 AM »

Pfizer, Merck and many Big Pharmas have invested massive but massive sums in a range of new cancer drugs known as Pd1 and PD1-1 inhibitors - results are not conclusive and toxicity is triggering serious side effects.
All these advances are likely to benefit from being partnered with Scancell's Immunobody and Moditope platforms which however, may on their own, exceed the results of those new drugs struggling through.
As Prof. Lindy Durrant prepares to address the American Association for Cancer Research today - my friends following this, wonder if the news is about to break more widely. and for anyone interested. 
Posted by: Al
« on: April 06, 2014, 10:46:56 AM »

RE: the Flash Boys - while a very interesting story, much like most technological breakthroughs, there is a short term advantage that after a period of great success, is quickly overcome by future technoligical breakthroughs.

And while I am happy that the issue seems to be getting resolved, as a long term (think decades) investor, I tend to not loose a lot of sleep over this stuff.

Here is another alternative perspective.

P.S.  I though Michael Lewis' previous book, The Big Short, was a fascinating read.
Posted by: Roger
« on: April 06, 2014, 10:28:53 AM »

A discussion today by knowledgeable bods on about the recent Patent Application for the Moditope platform.
A 'second use' is listed - an epitope for treating auto-immune disease and for stimulating anti-inflammatory cytokine IL10 for that purpose.
This opens up the possiblility of new non-toxic treatments for arthritis, MS, lupus etc.
Stunning stuff.
Sorry TT - your 9.22 is fascinating but needs a new thread maybe ?
Posted by: Taman Tun
« on: April 06, 2014, 09:22:19 AM »

This is from the Guardian. Scary:-
Light travels at 186,000 miles a second in a vacuum, which is another way of saying that it covers 186 miles in a milli-second – a thousandth of a second. Given that much of our contemporary electronic communications are conveyed by pulses of light travelling along fibreoptic cables, we are given to extravagant hyperbole about the "death of distance". After all, if a message – or a file – can traverse the globe in the blink of an eye, it doesn't matter whether your hard drive is on your desktop or in a server farm in Nebraska or Sweden.

Flash Boys
by Michael Lewis
Buy the book
Tell us what you think: Star-rate and review this book
But it turns out that the speed of light is of great practical interest to some people. One group of them have shelled out $300m to lay a fibreoptic cable in a straight line from Chicago to New York. This involves, among other things, drilling through mountains and under urban areas. And for what? So that the time taken to send a signal between New York and Chicago could be reduced from 17 milliseconds to 13. For that apparently infinitesimal improvement, stock market traders were willing to pay $14m a year, plus a substantial upfront payment, to use the cable.

Therein lies the tale of Michael Lewis's enthralling new book, Flash Boys, which joins an elite but growing list of volumes that set out to explain how computing is reshaping our world. For it turns out that for people armed with the right kit, software and networking skills, an advantage of a few milliseconds is enough to let them turn a $14m annual subscription into annual profits of $20bn.

These people are called high-frequency traders – "high-frequency" because they are incredibly active (they submit almost 99% of the orders on US stock markets) and buy and sell shares in milliseconds. They are not really "traders" in any normal sense of the term, but software algorithms, and they now dominate the most important stock markets in the capitalist world.

Most of us knew that, sort of. We knew about computerised trading and probably naively assumed that it was more efficient than the old system of guys in coloured jackets bellowing at one another on the floor of an exchange. Well, it is more efficient – for some. But the significance of Lewis's book is that it explains in user-friendly terms how the colossal profits of high-frequency traders really amount to an unconscionable tax on the ordinary investor, or at any rate on the pension funds and other financial institutions on which our livelihoods depend.

Flash Boys follows the usual Lewis formula: find a scandalous situation that is too arcane for most people to comprehend; locate some smart guys (they are usually male) who have spotted the scam and plan to do something with or about it; and tell their story.

In his earlier book The Big Short, Lewis focused on the smallish group of shrewd investors who understood that the sub-prime mortgage boom was sure to go bust and bet against it. In his new book, the white hat is worn by Brad Katsuyama, a Royal Bank of Canada trader who discovered the extent to which high-frequency traders were skewing the stock market and screwing investors and, in the end, set up a new stock exchange (IEX) designed to level the playing field by making sure everyone's trading instructions arrived at the same time.

But the most interesting thing about Flash Boys is what it reveals about the networked world into which we have stumbled. Once upon a time the New York stock exchange was a place; now it's a set of more than a dozen "stock exchanges" scattered around New York and New Jersey. But these exchanges are not places either: they are server farms, air-conditioned warehouses filled with rack-mounted computers, complete with blinking lights and whirring discs.

So the stock market has become a virtual space – an interactive, computer-driven system of staggering complexity. And it turns out that there are several sides to this complexity: for the banks and the high-frequency traders who exploit it, it's a marketing tool for bamboozling investors and a means of intimidating regulators; and for smart programmers and entrepreneurs it offers limitless opportunities to play the system.

"From the point of view of the most sophisticated traders," Lewis writes, "the stock market wasn't a mechanism for channelling capital to productive enterprise but a puzzle to be solved."

For society, the system's complexity is dangerous, because complex systems are intrinsically unpredictable and nobody really understands this one as a whole – which means that catastrophic failure is always a remote but finite possibility.

At first sight, the modus operandi of high-frequency traders seems so outrageous that one assumes it must be illegal. In its review, the Economist came up with a useful everyday analogy: high-frequency traders are like "the people who offer you tasty titbits as you enter the supermarket to entice you to buy; but in this case, as you show appreciation for the goods, they race through the aisles to mark the price up before you can get your trolley to the chosen counter". How, one wonders, can it be legal for a handful of insiders to operate at faster speeds than the rest of the market and, in effect, steal from investors?

But it is legal, and for an interesting reason. In 2004 the US Securities and Exchange Commission discovered that some traders in the old New York stock exchange were exploiting the discretion then allowed to them in choosing the time to execute a deal. The following year the SEC passed a new regulation, known as Reg NMS, which obliged traders to seek "the best price" for a security.

What the SEC did not anticipate was that in the new fragmented system of a dozen virtual exchanges, this provided the opportunity for high-frequency traders to outrun the market while staying within the law. Reg NMS was a well-intentioned measure to restore equality of opportunity in the US stock market. But instead, as Lewis points out, "it institutionalised a more pernicious inequality. A small class of insiders with the resources to create speed were now allowed to preview the market and trade on what they had seen."

This is a good illustration of one of the central problems that society will have to address in the coming decades: the collision between analogue mindsets and digital realities.

Software is pure "thought-stuff". The only resource needed to produce it is human intelligence and expertise. This has two implications. The first is that attempting to regulate the things that it creates is like trying to catch quicksilver using a butterfly net.

The Edward Snowden disclosures about the US National Security Agency have revealed how difficult it is to bring this stuff under effective democratic control. Lewis's account of how high-frequency trader geeks have run rings around the regulators suggests that much the same holds true in civilian life. This technology can easily run out of control.

The second implication is that what one might call the politics of expertise will become much more important. Mastery of these technologies confers enormous power on those who have it. Sed quis custodiet ipsos custodes and all that. So in addition to wondering who will guard the guardians, we may have to start thinking about who is going to guard the geeks.
Posted by: Roger
« on: April 05, 2014, 08:02:14 PM »

On Monday, Prof. Lindy Durrant, CEO of Scancell, addresses the 'American Association for Cancer Research' which is attended by 18000 persons of knowledgeable status, an event of significance. You can access an abstract of Scancell's work with SCIB1 for advanced melanoma, on the AACR sites.
Companies with similar 'advances' in this field are not getting there.
I predict 2 Nobel prizes for Prof. Lindy, one for Immunobody and one for Moditope.
Still below the radar - this is a good share to pop into a 2014/5 ISA - all IMHO.

Posted by: Roger
« on: February 18, 2014, 08:01:05 PM »

And Pfizer keep getting mentioned as a suitor - they having recently made a deal with 'Ichor' in the USA for access to the technology which SCLP use under agreement with Ichor, to inject their vaccines - it involves a local electrical charge with the injection increasing it's effects. GL
Posted by: Roger
« on: February 18, 2014, 07:57:11 PM »

Well in the last week or so, SCLP (Scancell) have been granted by the FDA, 'Orphan Drug Status' for the Phase 3 development of their Immunobody SCIB1 vaccine for Melanoma. Getting the product to the market then has massive tax reliefs for it's development in the USA and protection from competitors for 7 years. Patents already in place.
AND, their second platform for vaccines, Moditope, has had it's patent published todayish, job done, but the details of what this should be able to do for healthcare in the future are astounding - moving outside cancers into many other conditions - including rheumatoid arthritis but some years away.
Serious stuff and you can look at under SCLP and read today's BB and see some very exciting stuff - 200 posts to work through - or look at under the RNS heading to see the official release.
The joint CE Prof. Lindy heading for Nobel IMVHO as always.
Posted by: Roger
« on: December 09, 2013, 03:03:42 PM »

Well the Scancell Phase 2 results have been announced - "the immune response data released today from our lead program, the SCIB1 Immunobody vaccine for advanced melanoma, has exceeded our highest expectations". The Immunobody method or platform can be used to address other cancers and in fact SCIB2 for lung cancer has already been fully tested on animals and is ready for further development.
The serendipity discovery of 'Moditope' is another Scancell asset under patent actions and the first Moditope product is being developed in the laboratory - this second platform can target many cancers, causing a cascade of what is known as killer T cells in the tumour site.
It is hoped that Scancells' Immunobody' vaccines can address early stage cancers and for more developed cancers can be used in conjunction with the new generation of PD-1 inhibitors that the major Pharmas have on stream now.
It is hoped that Moditope science can address more advanced cancers
The Scancell treatments have no serious side effects.
You can read more about Investors discussing this on input SCLP. 'Puritas', 'Inanaco', 'Wildforce' and 'Crumbs' always worth reading.
The official announcements can be read on LSE under the RNS section or on Scancells' website,
Johnnie please if you could post a tube called 'Investor Day' from Prof. Lindy Durrant (2.10.2013) and another Dr Richard Goodfellow (9.12.2013) from Scancell's website, anyone interested can watch/listen some more.
Sorry I'm not more technically competent to tell you more about it myself.
Advances like this will mean that cancer becomes a chronic rather than terminal disease in the years to come.

Posted by: Roger
« on: October 02, 2013, 08:19:27 AM »

Impressive Investors Day yesterday. SP is around 38p now, inexplicably low. IMHO SCLP is a once in a lifetime investment opportunity.
What Scancell has will be, IMHO, the biggest step function in the medical world since the advent of antibiotics.
A massive Company like Merck with an R&D budget of $8 billion, falling over their patent cliff, slashing R&D 16,000 jobs, has a main focus on developing a cancer drug categorised as a PD-1 inhibitor, which Scancell's platforms can improve or replace without toxicity.
Last week a major splash in DM about a new drug called 'Ipilimumab' (or similar) which can work but has awful side effects. But Scancell's platforms dwarf what their product can do.
Merck already have longstanding options to negotiate for 5 target vaccines. The CE talked yesterday of interest from Roche.
DYOR Guys and up to you.
You can read up daily on Read Puritas, Boommorbust and Inanaco - ignore the banter. Serious reading.
You can ignore me on LSE as 'Torquay Fan'.
Also you can look at for RNS disclosures.
A paltry $1 billion is £3 a share.
I'm not 'ramping' just trying to alert.
And it will be really wonderful to have a massive range of effective non-toxic treatments coming through for oncology and other infectious diseases.
Posted by: Roger
« on: August 03, 2013, 03:14:58 PM »

The news from Scancell is gathering pace. Completion of the Phase 2 trial, SCIB1 for melanoma, is expected by the end of this year - words like 'extremely exciting' are being used. Secondary tumours have even been taken away in some patients in trial.
The 'Immunobody' platform from which SCIB1 derives, can be reprogrammed to develop vaccines for many or all different cancers, and possibly other infectious diseases. The 'serendipity' discovery of a second platform, 'Moditope', last year, is even more exciting. Moditope, surprisingly 'modified epitopes', has been found to have a 'sweet synergy' (in the words of the Prof. Lindy Durrant), with Immunobody, and they are just bubbling with the excitement of it. Announcements are expected in the next few weeks about progress with Patent Applications for the Moditope science, due 12 months after the applications were launched.
In October there is a publicity meeting for Investors - previously SCLP have done almost no PR at all.
IMHO this is going to be a massive development to benefit the World and the Share Price will rise significantly, (at the moment the SP has dropped due to a Cash Call and the vagaries of the AIM market).
ASOS is the top AIM performer - from 20p to £46 - a bloody dress shop !

On Thursday there was a General Meeting and some of my Mates went - Peter, (who lives in Hua Hin area), spoke to Prof. Lindy alone for 10 minutes afterwards and she is SO excited. Nobels coming for her IMO.

Take a look Guys -
Also, LSE.CO.UK/SCLP. Look at some chat posts Thursday/Friday from 'Dragon', 'Ciaskin', 'CC24601' and 'Inanaco' - for interesting views of the Meeting.

100's of different therapeutic vaccines can be developed with this science.
All being well - sweet synergy !
Posted by: Roger
« on: June 21, 2013, 08:56:40 AM »

Johnnie - I hadn't noticed that you had posted Prof. Lindy's video as well as Dr Richard Goodfellow's. Thanks.
Lindy is lovely and I beat the whole BB on SCLP to making her my Valentine on Feb 14th - I wake up earlier than the rest !
My prediction is that she will certainly get the Nobel prize for Medicine within a few years, for the 'Immunobody' vaccine platform and maybe later, another one, (is that possible?), for the 'Moditope' serendipity discovery.
Big Pharmas have gone off a patent cliff and need new directions - we hope the bidding war for SCLP will be, let's say, interesting.
Posted by: Roger
« on: June 21, 2013, 07:56:45 AM »

Morning all. After two recent days which had + 10% rises, the SCLP shares are back at the 49p in December last !
Yesterday, +15% on a day when the FTSE dropped 3%.
Do Your Own Research (DYOR) and make your own decision, but this is not a bad place for a punt.
The most important aspect is, that if Scancell's work comes through, and all the indications are that it is far ahead of any other development in cancer treatment, their vaccines will change the prospects for cancer sufferers, beyond all recognition.
Anyone interested can look at (Johnnie has posted a link to a video above), or
On the lse site, dig back through the pages and call up all postings from 'Puritas' - startling technical stuff in there.
These shares may go down today, but over 4-6 months, IMHO, the only way is up !
Nice day all.
Posted by: Johnnie F.
« on: March 26, 2013, 10:09:58 PM »

Posted by: Roger
« on: March 26, 2013, 06:09:23 PM »

Johnnie - on there is a 'link' posted by WILDFORCE at 16.43 yesterday.
May I ask if you would be kind enough to post the link on here. It's Professor Lindy Durrant talking about the cancer vaccines.
(An old one, but well worth a view)
It will help keep the thread complete as it may attract increasing interest this year.
Posted by: Roger
« on: March 13, 2013, 04:18:09 PM »

Thank you Johnnie. Ain't technology wonderful !
Posted by: Johnnie F.
« on: March 13, 2013, 03:14:06 PM »

Typing a Youtube link without any further codes around it makes the video appear directly and centered in a window in the post. If you want to go to Youtube to read the discussion there click the blue link below the window.

Interview with Dr. Richard Goodfellow, CEO of Scancell Holdings PLC (27th Feb 2013)
Posted by: Roger
« on: March 13, 2013, 02:54:41 PM »

BF. The link is
I typed that as couldn't pick the link up. Sorry.
Otherwise - under 'about us'.
Posted by: Baby Farts
« on: March 13, 2013, 09:25:34 AM »

Roger, can you post a link to the youtube video?  I can't find it.


Posted by: Roger
« on: March 13, 2013, 06:25:46 AM »

On - the Joint CE has now posted a 6 minute Youtube - under 'About Us'. A first bit of PR at last.
'Immunobody' is widely patented already - a train of science for making the cancer vaccines and 'Moditope', (modified epitopes), 100+ patents pending, prepares the body to receive the vaccine effectively by activating the immune system. Startling stuff !
If you are interested, the SCLP website has many details and you can look at for the share chat. Access recent posts over the last week, by say Puritas and Inanaco - for knowledgeable insights.
Apparently, penicillin was a 'serendipity' discovery and so was 'Moditope' - our Prof. Durrant 'dancing for joy'. Some wiseacre also posted that Viagra too was a chance discovery - that caused some excitement!
Posted by: Roger
« on: March 01, 2013, 07:10:03 AM »

No responses to my post in December and I'm grateful for that in a way, because I would not want to lead anyone else to have a punt on this. DYOR as they say on the BB's. (Oh actually, the SP has fallen from 49p to 33p - just the nature of AIM).
Everyone knows the tragedy of cancer and of course, it has touched the lives of many of us.
The science in the work of SCLP seems truly startling. They have 5 or 6 vaccines, including melanoma, lung, and prostate, under development at the moment under a patented 'Immunobody' platform. The melanoma vaccine is in Phase 2 trials and having very good results for Stage3/4 patients who would have had only a few months to live.
They also discovered a modified epitope 'Moditope', purely by chance, and have over 100 patent applications pending - a second way to enhance the vaccine process apparently not just for oncology, but other infectious diseases too.
And the vaccines may be able to be used as a preventative as well as a treatment.
These are really interesting developments in Science and well worth a read. You can look at or and read the official RNS statements.
There was a big article in the DM a years ago under the heading 'Holy Grail' or something but the Company are avoiding PR generally as
the response would be too difficult to handle. I've been following this for a year and it is very exciting IMO.
If you have some time, have a read of it. It is just very interesting.
Prof. Lindy Durrant has been working on this for 20 years and the research train started when she treated 2 young girls with advanced terminal bone cancer - now they are both grown up, well and with Children. (one Amy Dickinson and one anonymous).
If there are any Scientists hiding on the Forum, would be glad to hear your views. Exciting stuff for the World - all being well.
Posted by: Roger
« on: December 06, 2012, 07:10:02 AM »

Realise I'm treading on difficult ground, but I want to share this. I have a few shares in an AIM listed Company, Scancell Holdings (SCLP) who are releasing data about a vaccine for treating Stage 3/4 melanoma within the next week or two. All the reading between the lines suggests this is very significant.
Also testing a vaccine for lung cancer and researching other cancers too.
In the course of their work, they came across a way of modifying 'epitopes' to attack different cancers and other diseases naturally - they have 100 patent applications in for 'Moditope'.
Shares stand at 49 p but could go ballistic at some stage. Eminent BOD have already said the vaccines part of the business will go to trade sale end of next year. $1billion will be the minimum in most views.
BOD know what they have. The share is already a ten bagger !
All IMHO and DYOR. Maybe a home for any spare dosh you have.
Look at (SCLP) and read up postings by Inanaco, PeggySue, Lucille-ball, Lucinda etc.
Regret I can't debate this as I am not technical, but it is worth a look if you have time.